Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.42 |
| ▸ | DRD3 | P35462 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1438103 | 0.92 | CNR2 (0.43) | CNR2DRD3MEN1KMT2AMOGAT2 | |
| SCHEMBL1437608 | 0.88 | MEN1 (0.47) | CNR2DRD3MEN1KMT2AMOGAT2 | |
| SCHEMBL12003603 | 0.88 | S1PR1 (0.40) | CNR2DRD3MEN1KMT2A | |
| SCHEMBL1438553 | 0.86 | CNR2 (0.48) | CNR2DRD3MEN1KMT2AMOGAT2 | |
| SCHEMBL1438033 | 0.86 | MEN1 (0.41) | CNR2DRD3MEN1KMT2A | |
| SCHEMBL1438286 | 0.86 | DRD3 (0.39) | CNR2DRD3MEN1KMT2A | |
| SCHEMBL1438291 | 0.86 | CNR2 (0.41) | CNR2DRD3MEN1KMT2AMOGAT2 | |
| SCHEMBL15153668 | 0.86 | MEN1 (0.45) | CNR2DRD3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL12003677 | 0.85 | CNR2 (0.48) | CNR2DRD3MEN1KMT2AMOGAT2 | |
| SCHEMBL1436982 | 0.85 | LMNA (0.41) | CNR2DRD3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273017-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2016-03-01 | — | — | US | disclosed |
| US-20150239857-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LIMITED (BS) | 2015-08-27 | — | — | US | disclosed |
| US-9045441-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2015-06-02 | — | — | US | disclosed |
| EP-2473490-B1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | disclosed |
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LIMITED (BS) | 2012-08-30 | — | — | US | disclosed |
| EP-2473490-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | Abbott Healthcare Products B.V. (NL) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011023795-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239857-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | CNR2 9/4885DRD3 246/4885MEN1 369/4885 |
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | CNR2 10/4885DRD3 302/4885MEN1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.